-
Mashup Score: 66
In this issue of the Journal, Antonia and colleagues report the results of the phase 3 PACIFIC study, which evaluated the role of immune checkpoint blockade in locally advanced, unresectable, stage…
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 56Upfront Versus Delayed Systemic Therapy in Patients With Oligometastatic Cancer Treated With SABR in the Phase 2 SABR-5 Trial - 1 month(s) ago
The optimal sequencing of local and systemic therapy for oligometastatic cancer has not been established. This study retrospectively compared progression-free survival (PFS), overall survival (OS), and SABR-related toxicity between upfront versus delay of systemic treatment until progression in patients in the SABR-5 trial.
Source: www.redjournal.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 9What You See Ain't Necessarily What You Got - 1 month(s) ago
This issue of the Red Journal presents novel combinatorial approaches (eg, advanced imaging with sophisticated planning and delivery tools). We herein take this opportunity to again highlight (1) our tendency toward an overreliance on imaging and (2) the utility of continuing to extend beyond imaging to incorporate anatomic and physiological concepts into the treatment planning process.1,2
Source: www.redjournal.orgCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 11Cancers - 2 month(s) ago
Cancers, an international, peer-reviewed Open Access journal.
Source: www.mdpi.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Palliative Quad Shot Radiation Therapy with or without Concurrent Immune Checkpoint Inhibition for Head and Neck Cancer - 2 month(s) ago
Objectives: Patients with recurrent and metastatic head and neck cancer (HNC) have limited treatment options. ‘QuadShot’ (QS), a hypofractionated palliative radiotherapy regimen, can provide symptomatic relief and local control and may potentiate the effects of immune checkpoint inhibitors (ICIs). We compared outcomes of QS ± concurrent ICIs in the palliative treatment of HNC. Materials and Methods: We identified patients who received ≥three cycles of QS from 2017 to 2022 and excluded patients without post-treatment clinical evaluation or imaging. Outcomes for patients who received QS alone were compared to those treated with ICI concurrent with QS, defined as receipt of ICI within 4 weeks of QS. Results: Seventy patients were included, of whom 57% received concurrent ICI. Median age was 65.5 years (interquartile range [IQR]: 57.9–77.8), and 50% patients had received prior radiation to a median dose of 66 Gy (IQR: 60–70). Median follow-up was 8.8 months. Local control was significantly
Source: www.mdpi.comCategories: General Medicine News, Oncologists2Tweet-
Alas, there is a way to improve Quad Shot! #radonc https://t.co/ZzjOw45IjZ A pharma-sponsored unplanned secondary analysis of the phase 3 LATITUDE trial establishing the efficacy of adding abiraterone to ADT for metastatic castrate sensitive prostate cancer demonstrates the… https://t.co/nDfnwalJek https://t.co/ovaggRHD7M
-
-
Mashup Score: 1Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy - Full Text View - ClinicalTrials.gov - 2 month(s) ago
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy – Full Text View.
Source: classic.clinicaltrials.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 9Johns Hopkins Fellowship Programs - 2 month(s) ago
The Johns Hopkins Proton Therapy fellowship is a clinical fellowship focused on learning the practice of proton therapy delivery, and includes many opportunities for educational and research engagement. Fellows participate in seeing consults, simulations and treatment planning for cases in the proton center at Sibley Memorial Hospital in D.C. Each fellow is encouraged to choose a number of research projects to work on throughout the year with faculty mentors in the department. Fellows participate in
Source: www.hopkinsmedicine.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 8Amid Major Cancer Care Bankruptcy, Oncology Clinics Sold - 2 month(s) ago
OneOncology and Coastal Cancer Center have purchased two radiation oncology centers from GenesisCare as part of that company’s effort to emerge from bankruptcy.
Source: www.obroncology.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 15Impact of Medical Operability and Total Metastatic Ablation on Outcomes After SABR for Oligometastases - 2 month(s) ago
Medical operability is prognostic for survival after SABR in primary malignancies. This study investigated the prognostic significance of medical oper…
Source: www.sciencedirect.comCategories: General Medicine News, Oncologists2Tweet-
We use a similar approach to @ChadTangMD in @PeterMacRadOnc @gu_onc #radonc. We often use SABR alone upfront in oligometastases. We reported a 3- and 5-year freedom from systemic therapy of 40% and 31% with this approach here (n=401, basket histology); https://t.co/7nnDpccrwM https://t.co/SQinSj9n2J https://t.co/AmjE04368P
-
-
Mashup Score: 17Varian Medical Systems to Introduce RapidArc™ Radiotherapy Technology for Volumetric Arc Therapy at ASTRO 2007 | Varian - 2 month(s) ago
ASTRO Booth # 419 — Varian Medical Systems (NYSE: VAR) today announced that it has developed groundbreaking technology for faster, more…
Source: www.varian.comCategories: General Medicine News, Oncologists2Tweet
"The data from the PACIFIC study may end the debate about the role of surgery in patients with stage III NSCLC, with durvalumab after chemoradiotherapy redefining best practice for all patients with stage III NSCLC." [NEJM 2017] #radonc https://t.co/SNNRCHgXSn https://t.co/CgkarcL7tx